John Devin Peipert
Biographic Data
| ID | 4889042 |
|---|---|
| NAME | John Devin Peipert |
| GIVEN NAMES | John Devin |
| FAMILY NAME | Peipert |
| SIGNATURE | PEIPERT J D |
| AFFILIATIONS | Northwestern University |
| ORCID | 0000-0001-5762-7881 |
| VERIFIED | Yes |
| TOTAL WORKS | 17 |
| TOTAL CITATIONS | 3 |
| AUTHOR COUNT | 17 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2013 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 1 |
Cosmin reporting guideline for studies on measurement properties of patient‐reported outcome measures: Version 2.0
Explanation & Elaboration document of the Cosmin Reporting Guideline 2.0 for studies on measurement properties of patient-reported outcome measures
Health-related quality of life in kidney transplant recipients: Association with graft function and comparison to patients on dialysis
Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04
GOV: NCT00058474
Patient-reported outcomes in non-small cell lung cancer: Psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials
Significant individual change should be used as a lower bound for anchor based estimates of meaningful change on patient-reported outcome scores
Interpretation of patient-reported outcome (PRO) scores has been supported by identifying score thresholds or ranges that indicate clinical importance. There has been a recent focus on the estimation of meaningful within patient change (MWPC). While much attention has been focused on anchor-based methods, some researchers prefer that a lower bound to these estimates should exceed a change score that could be observed due to measurement error alon…
International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials
In June 2021, the US Food and Drug Administration (FDA) released a draft guidance for industry on core patient-reported outcomes (PROs) and related considerations for instrument selection and trial design in registrational cancer clinical trials, building on prior communications about the use of PROs to assess efficacy and tolerability in oncology drug development. The International Society for Quality of Life Research (ISOQOL) Standards and Best…
Likely change indexes improve estimates of individual change on patient-reported outcomes
Comparison of raw and regression approaches to capturing change on patient-reported outcome measures
Identifying meaningful change on PROMIS short forms in cancer patients: A comparison of item response theory and classic test theory frameworks
Applying the two-step criteria demonstrated in this study, we determined how much change is needed to declare reliable change at different levels of baseline scores. We offer reference values for percentage of patients who meaningfully change for investigators using the PROMIS instruments in oncology
Trends and predictors of multidimensional health-related quality of life after living donor kidney transplantation
Differential item functioning of the CAHPS® In-Center Hemodialysis Survey
Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients
Negligible impact of differential item functioning between Black and White dialysis patients on the Kidney Disease Quality of Life 36-item short form survey (KDQOLTM-36)
Invariance of measures to understand decision-making for pursuing living donor kidney transplant
Living donor kidney transplant is the ideal treatment option for end-stage renal disease; however, the decision to pursue living donor kidney transplant is complex and challenging. Measurement invariance of living donor kidney transplant Decisional Balance and Self-Efficacy across gender (male/female), race (Black/White), and education level (no college/college or higher) were examined using a sequential approach. Full strict invariance was found…
Measuring kidney patients' motivation to pursue living donor kidney transplant: Development of Stage of Change, Decisional Balance and Self-Efficacy measures
While educational interventions to increase patient motivation to pursue living donor kidney transplant have shown success in increasing living donor kidney transplant rates, there are no validated, theoretically consistent measures of Stage of Change, a measure of readiness to pursue living donor kidney transplant; Decisional Balance, a weighted assessment of living donor kidney transplant's advantages/disadvantages; and Self-Efficacy, a measure…
Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (Facit TS) measures
Measuring kidney patients' motivation to pursue living donor kidney transplant: Development of Stage of Change, Decisional Balance and Self-Efficacy measures
While educational interventions to increase patient motivation to pursue living donor kidney transplant have shown success in increasing living donor kidney transplant rates, there are no validated, theoretically consistent measures of Stage of Change, a measure of readiness to pursue living donor kidney transplant; Decisional Balance, a weighted assessment of living donor kidney transplant's advantages/disadvantages; and Self-Efficacy, a measure…
Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (Facit TS) measures
Measuring kidney patients' motivation to pursue living donor kidney transplant: Development of Stage of Change, Decisional Balance and Self-Efficacy measures
While educational interventions to increase patient motivation to pursue living donor kidney transplant have shown success in increasing living donor kidney transplant rates, there are no validated, theoretically consistent measures of Stage of Change, a measure of readiness to pursue living donor kidney transplant; Decisional Balance, a weighted assessment of living donor kidney transplant's advantages/disadvantages; and Self-Efficacy, a measure…
Invariance of measures to understand decision-making for pursuing living donor kidney transplant
Living donor kidney transplant is the ideal treatment option for end-stage renal disease; however, the decision to pursue living donor kidney transplant is complex and challenging. Measurement invariance of living donor kidney transplant Decisional Balance and Self-Efficacy across gender (male/female), race (Black/White), and education level (no college/college or higher) were examined using a sequential approach. Full strict invariance was found…
Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients
Negligible impact of differential item functioning between Black and White dialysis patients on the Kidney Disease Quality of Life 36-item short form survey (KDQOLTM-36)
Differential item functioning of the CAHPS® In-Center Hemodialysis Survey
Trends and predictors of multidimensional health-related quality of life after living donor kidney transplantation
Likely change indexes improve estimates of individual change on patient-reported outcomes
Comparison of raw and regression approaches to capturing change on patient-reported outcome measures
Identifying meaningful change on PROMIS short forms in cancer patients: A comparison of item response theory and classic test theory frameworks
Applying the two-step criteria demonstrated in this study, we determined how much change is needed to declare reliable change at different levels of baseline scores. We offer reference values for percentage of patients who meaningfully change for investigators using the PROMIS instruments in oncology
International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials
In June 2021, the US Food and Drug Administration (FDA) released a draft guidance for industry on core patient-reported outcomes (PROs) and related considerations for instrument selection and trial design in registrational cancer clinical trials, building on prior communications about the use of PROs to assess efficacy and tolerability in oncology drug development. The International Society for Quality of Life Research (ISOQOL) Standards and Best…
Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04
GOV: NCT00058474
Patient-reported outcomes in non-small cell lung cancer: Psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials
Significant individual change should be used as a lower bound for anchor based estimates of meaningful change on patient-reported outcome scores
Interpretation of patient-reported outcome (PRO) scores has been supported by identifying score thresholds or ranges that indicate clinical importance. There has been a recent focus on the estimation of meaningful within patient change (MWPC). While much attention has been focused on anchor-based methods, some researchers prefer that a lower bound to these estimates should exceed a change score that could be observed due to measurement error alon…
Cosmin reporting guideline for studies on measurement properties of patient‐reported outcome measures: Version 2.0
Explanation & Elaboration document of the Cosmin Reporting Guideline 2.0 for studies on measurement properties of patient-reported outcome measures
Health-related quality of life in kidney transplant recipients: Association with graft function and comparison to patients on dialysis
Medicine (15 works) · Internal Medicine (10 works) · Health Systems, Economic Evaluations, Quality of Life (8 works) · Psychology (8 works) · Quality of life (healthcare (7 works) · Clinical Psychology (6 works) · Nursing (6 works) · Physical therapy (6 works) · Clinical Psychology (5 works) · Item response theory (5 works)